Table 2.
Time to progression: Kaplan-Meier rates
| Patient Variables | 1-Year Progression Rate (%) | 3-Year Progression Rate (%) | Median Months to Progression |
|---|---|---|---|
| All cases | 17.3 | 39.4 | 53.7 |
| Age (years) | |||
| 2 to 5 | 11.8 | 28.6 | 78.6 |
| 6 to 12 | 16.0 | 38.4 | 52.8 |
| >12 | 21.6 | 46.9 | 40.9 |
| Gender | |||
| male | 16.5 | 37.9 | 57.5 |
| female | 18.6 | 42.0 | 48.0 |
| Race | |||
| white | 16.3 | 37.5 | 60.3 |
| African American | 19.5 | 44.1 | 43.9 |
| Hispanic | 17.3 | 41.2 | 47.1 |
| other | 21.0 | 41.5 | 51.8 |
| Primary diagnosis | |||
| obstructive uropathy | 10.8 | 29.4 | 67.2 |
| focal segmental glomerulosclerosis | 31.7 | 61.7 | 22.9 |
| renal dysplasia | 14.3 | 39.3 | 54.0 |
| reflux nephropathy | 10.5 | 28.4 | 88.5 |
| other | 18.2 | 39.7 | 52.3 |
| CKD stage | |||
| stage II | 3.5 | 15.4 | 137.7 |
| stage III | 8.6 | 28.8 | 67.8 |
| stage IV | 43.0 | 74.5 | 15.5 |
| Hypertension | |||
| yes | 21.0 | 44.8 | 43.8 |
| no | 14.2 | 34.5 | 63.7 |
| Laboratory values at registration | |||
| anemia | |||
| HCT ≥33% | 10.3 | 28.2 | 77.3 |
| HCT <33% | 29.0 | 57.6 | 26.2 |
| calcium | |||
| low | 33.5 | 53.3 | 29.1 |
| normal | 16.9 | 39.3 | 52.7 |
| high | 17.1 | 40.3 | 55.6 |
| phosphorus | |||
| normal | 10.9 | 29.8 | 70.1 |
| high | 32.3 | 62.5 | 23.6 |
| albumin | |||
| ≤4.0 g/dl | 24.5 | 52.2 | 32.2 |
| >4.0 g/dl | 10.4 | 27.6 | 74.6 |
| Medication use at registration | |||
| anti-hypertensive medication use | |||
| yes | 21.5 | 45.7 | 42.7 |
| no | 13.7 | 34.1 | 64.0 |
| erythropoietin use | |||
| yes | 40.9 | 68.8 | 17.7 |
| no | 13.7 | 34.8 | 61.2 |
| iron supplementation | |||
| yes | 29.2 | 56.3 | 28.8 |
| no | 13.5 | 34.0 | 63.7 |